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Abstract
Background: The long-term impact of opioid maintenance treatment (OMT) on morbidity and health care
utilization among heroin addicts has been insufficiently studied. The objective of this study was to investigate
whether health care utilization due to somatic disease decreased during OMT, and if so, whether the reduction
included all kinds of diseases and whether a reduction was related to abstinence from drug use.
Methods: Cohort study with retrospective registration of somatic disease incidents (health problems, acute or
sub-acute, or acute problems related to chronic disease, resulting in a health care contact). Medical record data
were collected from hospitals, Outpatients' Departments, emergency wards and from general practitioners (GPs)
and prospective data on substance use during OMT were available from 2001 onwards. The observation period
was five years before and up to five years during OMT. The cohort consisted of 35 out of 40 patients who received
OMT between April 1999 and January 2005 in a Norwegian district town. Statistical significance concerning
changes in number of incidents and inpatient and outpatient days during OMT compared with the pre OMT
period was calculated according to Wilcoxon signed rank test. Significance concerning pre/during OMT changes
in disease incidents by relation to the type of health service contacts, as well as the impact of ongoing substance
use during OMT on the volume of contacts, was calculated according to Pearson chi-square and Fisher's exact
tests.
Results: 278 disease incidents were registered. There was a reduction in all incidents by 35% (p = 0.004), in
substance-related incidents by 62% (p < 0.001) and in injection-related incidents by 70% (p < 0.001). There was
an insignificant reduction in non-fatal overdose incidents by 44% (p = 0.127) and an insignificant increase in non-
substance-related incidents by 13% (p = 0.741). Inpatient and outpatient days were reduced by 76% (p = 0.003)
and 46% (p = 0.060), respectively. The disease incidents were less often drug-related during OMT (p < 0.001).
Patients experienced a reduction in substance-related disease incidents regardless of ongoing substance use,
however there was a trend towards greater reductions in those without ongoing abuse.
Conclusion: Although as few as 35 patients were included, this study demonstrates a significant reduction in
health care utilization due to somatic disease incidents during OMT. The reduction was most pronounced for
incidents related to substance use and injection. Inpatient and outpatient days were reduced. Most probably these
findings reflect somatic health improvement among heroin addicts during OMT.
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Background
Opioid addicts, especially injecting heroin users, suffer
increased health problems [1-3] and reduced health
related quality of life (HRQOL) [4-7] as well as increased
mortality, compared to the general population [8-10].
This is particularly related to overdoses [11-14], injuries
[9], human immunodeficiency virus (HIV)-infection
[9,11], viral hepatitis B (HBV) [15,16] and viral hepatitis
C (HCV) [16,17] with end-state liver disease and other
infections like endocarditis [9], osteomyelitis [18] and
others [19,20]. Several studies and case reports demon-
strate vulnerability among injecting drug users (IDUs) to
rare infectious diseases like tetanus [21], botulism [22,23]
and gas gangrene due to Clostridium [21,24-27].
Increased prevalence of various psychiatric diseases
among substance users is well documented in population
surveys and among persons entering opioid maintenance
treatment (OMT) [28-33].
In spite of considerable morbidity, drug users frequently
neglect their health problems, and diseases may remain
untreated. Several studies describe that patients with
extensive drug use cause problems in hospitals [34] and
are difficult to treat in ordinary general practice. Yet some
studies based on central health registers show increased
health care utilization, in particular due to intoxications/
overdoses, infections related to illicit drug use and injuries
[35].
OMT leads to reduced illegal opioid use and injection [36-
39] which probably reduces overdoses and infections. It is
also likely that OMT improves nutritional status and gen-
eral health. Moreover, OMT patients may become more
motivated to seek medical help, and OMT may remove or
at least reduce tension between patients and health service
providers, thus leading to improved health care follow-
up. It is therefore reasonable to assume that over time
OMT will reduce morbidity and mortality. Reduction in
mortality during OMT has been shown in observational
studies [11], but in two recent meta-analyzes of ran-
domised controlled trials (RCTs) mortality reduction
could not be documented [36,38]. However, this might be
due to problems applying RCT design in studies on OMT
effects versus placebo or no treatment [40]. Some studies
have shown improved psychological well-being, reduced
frequency of self-reported physical health problems, and
improved self-perceived HRQOL during OMT [37,41].
Except for this, documentation of OMT-induced health
effects is poor [42]. Consequently observational studies
with careful design might increase the understanding of
OMT effects on health care utilization and also on mor-
bidity.
With a national OMT program implemented during a
short time span and a well documented and severe illicit
drug problem [39], Norway is well suited for such studies.
The number of IDUs in Norway is estimated to 8 200 – 12
500 persons out of a population of 4.7 millions in 2005
[43]. The number of OMT patients December 31th 2005
was 3 614 [44]. Although heroin is usually injected [45]
the prevalence of HIV among heroin users is as low as 1–
2% [46]. The cumulative number of IDUs infected with
HIV from the early 1980s until 2006 is 528 [46]. The anti-
HCV antibody prevalence among IDUs is 70–80% [47]
and approximately 2/3 of these are Polymerase Chain
Reaction (PCR) positive [48]. The death rate among drug
users has been estimated to about 1–2% per year [45]. The
number of registered overdose deaths has been high with
a peak of 405 in 2001 falling to 231 in 2004 [45]. Severe
psychiatric co-morbidity ("double-diagnosis") is docu-
mented in about 1/3 of IDUs [49].
The national OMT program keeps overall surveillance of
patients entering and leaving. Entrance depends on spe-
cific criteria [39]: patients should be at least 25 years old,
have been dependent on opioids for "several" years and
have undergone abstinence-oriented treatment. Treat-
ment is ended if patients fail to pick up the medication
over time, and may be involuntary terminated if patients
show continued illicit drug use, sell the OMT-medication
or illegal drugs, act threatening or violent towards treat-
ment personnel or show severe lack of willingness to fulfil
the program regulations. Authorized regional centres
cooperate with municipal social service and GPs. Only
methadone and buprenorphine are accepted as substitu-
tion medication and the average dosage level is high: 114
mg and 18 mg respectively in 2005 [44]. Retention in
treatment – which means the proportion of patients who
stay in the program over time – is high, compared to most
other countries [39].
The systematic collection of information on all partici-
pants in the OMT-program as well as computer-based
record systems in primary health care and hospitals make
Norway suitable for detailed studies of OMT related
health effects. The objective of this study was to investi-
gate health care utilization due to somatic disease before
versus during OMT in a cohort of OMT-patients. The
hypothesis was that such health care contact would
decrease during OMT, mainly due to reduced health prob-
lems related to illicit drug use and injection. Further, we
wanted to investigate whether such possible reduction
would occur only in patients who stayed abstinent from
illicit drug use or also among those with ongoing abuse.
Methods
Our study compares health care utilization due to somatic
disease before versus during OMT using a retrospective
cohort design.BMC Public Health 2008, 8:43 http://www.biomedcentral.com/1471-2458/8/43
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Study population
The study was carried out in Gjoevik, a district town with
28 000 inhabitants and with considerable drug problems.
OMT was started locally in 1999, according to the guide-
lines of the national program. However, over the years the
GPs have come to play a more important role than is typ-
ical for OMT in Norway. Further, very few patients, even
among those with ongoing substance use, have had their
treatment involuntarily terminated, rather they have
received increased follow-up by GPs and social workers.
Outcome concerning social rehabilitation and continued
substance use during OMT has been close to national
average [50]. By the end of 2005, all 40 patients who had
started OMT were still in treatment, and 36 consented to
participate in the study. Data were not collected for one
person, rendering 35 participants (87.5%). Key character-
istics of the study population are summarized in Table 1.
The observation period was five years prior to and up to
five years during OMT; the mean observation period dur-
ing OMT was 35 months. Three patients temporarily ter-
minated OMT and then restarted. Disease incidents and
health care utilization that occurred while the three
patients were between OMT periods (in total five years)
were counted as pre-OMT.
Data sources
Thirty-two of the participants were interviewed about dis-
ease incidents during OMT and the years prior to OMT.
One of the authors (IS, physician) performed all inter-
views, which took place in a primary care centre or in the
patient's home. As no validated questionnaire suitable for
collecting this information was available, a list of relevant
diagnoses (Table 2) was used, as well as Time-line Follow-
back procedures, in order to facilitate remembering dis-
ease incidents and treatment.
Based upon the information obtained in the interviews,
records from hospitals, emergency wards and GPs were
collected. For the three persons not interviewed, hospital
records were collected based upon information in their
GPs' records. All requested records concerning inpatient
treatment, treatment in Outpatients' Departments (in
Norway these are hospital units), emergency wards (in
Norway these are part of the primary health care and
staffed by GPs), and 75 out of 82 records from solo GPs
and GP groups (in Norway most GPs work together in
groups of 3–5 sharing a joint record system) were received
and scrutinized. Data collection was concluded in June
2005. All data on diagnosis and health care utilization
presented in the study originate from these records.
Admissions and health care visits mentioned by patients
which could not be verified from records were not
included. Records from hospitals and GPs which had not
been specified by the participants were not requested.
Measures
A "disease incident" was defined as a health problem,
acute or sub-acute, resulting in a health care contact. Only
somatic incidents were counted, psychiatric illness was
only considered if it caused a somatic incident, e.g. an
injury due to self harm. A disease incident could be an iso-
lated case, for instance an overdose, an infection or an
injury, or a new incident due to an underlying chronic dis-
ease, for instance an asthma attack. Even if a disease inci-
dent lead to more than one health care visit, e.g. follow-
up visits for a fracture, it was registered as one incident.
Routine hospital or GP check ups for chronic diseases or
repeated treatment visits for a chronic disease, e.g. hepati-
tis C, were not included. Disease incidents documented in
several records, e.g. from a hospital and a GP, were only
counted once. We also counted number of inpatient treat-
ment days (inpatient days) and treatment days in hospi-
tals' Outpatients' Departments (outpatient days) due to
the disease incidents we registered.
The full-text records were scrutinized by one of the
authors (IS). ICD-10 [51] diagnoses from hospitals and
ICPC [52] diagnoses from GPs were registered. Based on
record information the disease incidents were categorized
Table 1: Cohort characteristics
Male Female
Gender, n (%) 22 (63) 13 (37)
Age at OMT-start, years, mean (range) 37.3 (29.4 – 50.5) 37.5 (27.3 – 50.3)
OMT medication, methadone, n 19 11
OMT medication, buprenorphine, n 3 2
Methadone dosage mg, median (range) 132.5 (100 – 220) 145 (100 – 170)*
Buprenorphine dosage mg, median (range) 22(16 – 32) 22 (20 – 24)
HCV antibody positive, n (%) 21 (95.5) 13 (100)
Receiving anti HCV treatment during OMT, n 1 0
HIV antibody positive, n 0 0
Died during OMT, n 0 0
*One outlier, 580 mgBMC Public Health 2008, 8:43 http://www.biomedcentral.com/1471-2458/8/43
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by mean of a diagnosis list developed for this study (Table
2). The list differentiates between drug related incidents
and others. Drug related incidents were categorized as
overdoses, injection related incidents and "others", like
rhabdomyolysis and related neuro-muscular damage
related to non-fatal overdoses, severe withdrawal reac-
tions, inpatient treatment because of severe exhaustion,
malnutrition and poor general condition due to drug use,
severe sub-acute dental health problems and several oth-
ers. The incidents not related to drug use were divided into
infections, injuries and "others", the latter including all
incidents not fitting into the specific categories.
Inter-rater agreement on relation to substance use and
diagnostic categories was estimated for 22 disease inci-
dents in six patients by two independent investigators (IS
and another physician). Agreement regarding relation to
substance use was perfect with a kappa value (κ) of 1.
When diagnostic groups were considered, κ was 0.82.
Information about ongoing use of illicit drugs and alco-
hol during OMT, based on urinary testing and clinical
assessment, was gathered from the annual reports made
for each OMT patient in Norway since 2001 [39]. For four
patients the treatment period was too short or provided
insufficient information on substance use; thus rendering
such information for 31 patients. The annual report scores
overall drug use during the last four weeks on a five-point
scale. In our study we simplified this to a dichotomized
score for the entire treatment period, differentiating
between "problematic" use with severe consequences for
psychosocial function versus "abstinence or non-prob-
lematic use" without such consequences.
Statistics and ethics
Wilcoxon signed rank test was used to compare changes in
rates of episodes before versus during OMT. Pearson chi-
square and Fisher's exact test were used to evaluate the
changes in the proportion of incidents related to sub-
stance use as well as assessment of health improvement
versus ongoing use of illegal drugs and alcohol during
OMT. Inter-rater agreement was estimated according to
Cohen's kappa. All statistical calculations were performed
in SPSS 14.0.
Table 2: Before/during OMT changes in disease incidents and inpatient and outpatient days. Number of somatic disease incidents* and 
inpatient and outpatient days* per 100 patient years before and during opioid maintenance treatment (OMT) in 35 patients.
Before OMT During OMT Reduction % Increase % P-value**
Incidents/treatment days per 
100 patient ears
Incidents/treatment days per 
100 patient years
Substance-related incidents
Overdoses (non-fatal) 17.7 9.9 44 0.127
Injection-related incidents, total*** 40.6 11.8 70 <0.001
Acute thromboembolic incidents 4.6 0.0
Acute hepatitis 1.7 0.0
Acute local infection 32.6 10.9
Acute/sub-acute general infection 1.7 1.0
Other substance-related incidents 21.7 8.9 59 0.087
Total 80.0 30.6 62 <0.001
Non-substance-related incidents
Infections 10.3 8.9 14 0.849
Injuries 20.6 19.7 4 0.832
Other incidents 12.6 20.7 64 0.375
Total 43.5 49.3 13 0.741
All incidents 123.5 79.9 35 0.004
Treatment days
Inpatient days 257.0 61.0 76 0.003
Outpatient days 59.0 32.0 45 0.060
*Definition of disease incident and treatment days, see text
**Wilcoxon signed rank test
***Overdoses not included, subcategories of incidents in italicBMC Public Health 2008, 8:43 http://www.biomedcentral.com/1471-2458/8/43
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The Regional Committee for Research Ethics approved the
study.
Results
Table 1 gives a summary of basic demographic and treat-
ment characteristics for the patient sample. The gender
distribution is typical for IDUs and mean age at OMT start
is 37 years. Treatment is high dosage, dominantly with
methadone as agonist. Nearly all patients are HCV-anti-
body positive, reflecting the dominant injecting drug use
pattern.
Altogether, 278 disease incidents were registered during
the observation period, 197 before and 81 during OMT.
Table 2 presents findings on health care utilization before
and during OMT. The overall reduction in disease inci-
dents was 35% (p = 0,004). There was a reduction of 62%
in substance-related incidents (p < 0.001), a 70% reduc-
tion in injection related incidents (p < 0.001), and an
insignificant reduction of 44 and 59% respectively in
overdoses and other substance-related incidents. There
was an insignificant increase of 13% in non-substance-
related disease incidents, exclusively in the group "other",
while infections and injuries showed minor change. Inpa-
tient and outpatient days due to somatic disease incidents
were reduced by 76% (p = 0.003) and 46% (p = 0.060)
respectively.
Table 3 shows the pre/during OMT shift in the distribu-
tion of disease incidents by relation to substance use.
Before OMT 62% of the incidents were related to sub-
stance use, compared to 36% during OMT (p < 0.001).
Table 4 displays health service contacts made during the
278 disease incidents. Forty per cent of all disease inci-
dents during OMT were documented exclusively by GPs,
compared with 25% before OMT (p = 0.02). Around 90%
of all hospital treatment, before as well as during OMT,
took place at the local hospital in Gjoevik.
Table 5 shows changes in disease incidents in nine
patients with and 22 patients without problematic sub-
stance use during OMT. Regarding injection-related inci-
dents, there was no difference between the groups, both
showing improvement. The reduction in all substance-
related incidents was greater for patients without prob-
lematic drug use, but the difference was not statistically
significant (p = 0.06). The reduction in the total number
of incidents was significantly greater for patients without
problematic drug use (p = 0.007).
Discussion
The primary goal of this study was to investigate how
OMT influences health service utilization in heroin
addicts. The study demonstrates a significant reduction in
health care contacts due to somatic disease incidents dur-
ing the five first years of OMT compared to the five previ-
ous years. This is a significant finding. Even if several
studies have shown severe morbidity among heroin
addicts, and some have found health improvement dur-
ing maintenance treatment [37,41], we have not been
able to find any study systematically comparing somatic
morbidity before OMT with morbidity during treatment,
based on record information.
The key question regarding the interpretation of our find-
ings is whether the observed reduction in health care uti-
lization can be seen as an indicator of health
improvement during OMT compared to the period
before. Firstly, how complete was the registration of
admissions and health care visits? The study cohort
includes nearly all OMT-patients in a defined area; hence
selection bias was not a problem. Recall bias could be a
problem, greater the further back we go. The patients'
information turned out to be chiefly correct, when con-
trolled against the records, regarding type of disease or
injury and where treatment had been received, but more
imprecise regarding the point of time. Each patient had on
average been treated at two GP centres, and approximately
90% of all hospital treatment had taken place at the local
hospital which shows a high degree of stability in the rela-
tion between treatment services and the patient group in
Table 4: Changes in type of health service contact. Before/during 
OMT changes in distribution of somatic disease incidents 
separated by type of health service contact. N = 278
Number of incidents (%)
GP* Hosp+**
Before OMT 49 (25) 148 (75)
During OMT 32 (40) 49 (60)
P-value 0.015***
*General practitioner
**Hospital/outpatient clinic/emergency ward
*** Pearson chi-square test
Table 3: Distribution of somatic disease incidents before and 
during OMT by relation to substance use. N = 278.
Relation to substance use* Before OMT (%) During OMT (%) P-value**
Related 123 (62) 29 (36)
Not related 74 (38) 52 (64)
Total 197 (100) 81 (100) <0.001
* Inter-rater agreement κ = 1.00
**Pearson chi-square testBMC Public Health 2008, 8:43 http://www.biomedcentral.com/1471-2458/8/43
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Gjoevik. The study thus comprises the majority of health
service contacts due to somatic disease incidents during
the study period.
Secondly, there will be a gap between the volume of dis-
ease in any patient sample, and what results in health
service contacts, and this is particularly so in a population
of IDUs [34]. Due to the structure of the treatment pro-
gram, contact between patients and the health services
was close during OMT, probably leading to increased
help-seeking and better medical follow-up and tending to
reduce the proportion of disease incidents not resulting in
a health service contact. Thirdly, the patients were five
years older during the OMT period, leading to increased
somatic morbidity. These factors all tend to increase the
volume of registered health care contacts during OMT.
Hence, when our study still shows a decline in utilization
of health services, this most probably is a proxy for an
improvement in somatic health status, and moreover, the
OMT-induced improvement is probably more extensive
than our findings indicate.
Even six out of nine patients with ongoing problematic
substance use during OMT experienced a reduction in
drug related disease incidents. The most likely explana-
tion is that they stop or at least reduce injecting drugs.
However, due to the increase in non-substance-related
disease incidents, the majority of patients with problem-
atic substance-use showed an increase in the total number
of incidents during OMT. This could be a consequence of
changed help-seeking behaviour and better medical fol-
low-up during OMT. If so, this finding reflects improved
follow-up and not a true rise in morbidity. On the other
hand, it is conceivable that patients with ongoing drug
abuse during OMT are more exposed to disease than those
without. However, because of the small number of
patients, and some uncertainty concerning the differenti-
ation between patients with and without ongoing prob-
lematic substance abuse, these results and their
significance should be interpreted with caution.
OMT is often evaluated primarily by its effect on social
rehabilitation and continued substance use. According to
our findings, this is not sufficient. Drug related disease
incidents were reduced even among patients with ongoing
abuse, though to a lesser degree. This might question
involuntary termination of OMT in patients who still take
illegal drugs.
The study has some weaknesses. The cohort is small and
limited to one local community. The research instru-
ments, especially the diagnosis categorisation system,
have not been validated by other researchers. In addition,
it is not always obvious whether a disease incident is
related to substance use or not. However, the high level of
inter-rater agreement on whether incidents were sub-
stance related or not (κ = 1) implies that this is possible to
differentiate.
In spite of these weaknesses, our study of a small patient
cohort showed a significant reduction in health care con-
tacts caused by somatic disease incidents during OMT
compared to the five years prior to treatment. These find-
ings ought to be further investigated in an enlarged study.
Table 5: Health care utilization versus ongoing illicit drug use during OMT. Number of patients with reduced, unchanged or increased 
rates of all, substance-related and injection-related somatic disease incidents respectively, in 22 patients with and 9 patients without 
problematic* illicit drug use during OMT
Diagnose group Change in incidents during versus before OMT, number of patients
Illicit drug use Reduction Unchanged Increase Total P value**
All incidents 0.007
Abstinence or non-problematic 18 1*** 3 22
Problematic 3 0 6 9
All substance-related incidents 0.063
Abstinence or non-problematic 18 3**** 1 22
Problematic 6 0 3 9
Injection-related incidents 0.503
Abstinence or non-problematic 15 6*** 1 22
Problematic 6 2*** 1 9
* Definition of problematic drug use, see text
**Chi-square Fisher's exact test: number of patients with increased versus reduced/unchanged rates of all, substance-related and injection-related 
incidents respectively, versus illicit drug use during OMT
*** Patients had zero episodes during both time periods
****Two of the three patients had zero episodesBMC Public Health 2008, 8:43 http://www.biomedcentral.com/1471-2458/8/43
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This could bring information about factors influencing
somatic health status changes during OMT, like psychiat-
ric co-morbidity or living in a larger city. The design cho-
sen appears suitable for investigating OMT-related
changes in somatic morbidity among heroin addicts in
Norway.
Conclusion
Even with as few as 35 patients included, this study dem-
onstrates a significant decrease in health care contacts due
to somatic disease incidents during OMT compared to the
five years before entering treatment. This reduction was
most striking for incidents related to substance use, and
drug injection in particular. Inpatient treatment days and
treatment days in hospitals' Outpatients' Departments
were reduced during OMT. These findings most probably
reflect an improvement in somatic health status for drug
abusers undergoing OMT compared to the period before
entering treatment.
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